✦ LIBER ✦

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

✍ Scribed by S. B. Hanauer; J. Panes; J.-F. Colombel; R. Bloomfield; S. Schreiber; W. J. Sandborn

Book ID: 108605982
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 239 KB
Volume: 32
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2010.04360.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomised clinical trial: improvement i

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

✍ B. G. Feagan; W. J. Sandborn; D. C. Wolf; G. Coteur; O. Purcaru; Y. Brabant; P. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB

Clinical trial: the effects of certolizu

Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn’s disease in the PRECiSE 2 study

✍ B. G. FEAGAN; M. C. REILLY; L. GERLIER; Y. BRABANT; M. BROWN; S. SCHREIBER 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

Predictive model for the outcome of infl

Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors

✍ Tibor Hlavaty; Marc Ferrante; Liesbet Henckaerts; Marie Pierik; Paul Rutgeerts; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

## Background: Infliximab (ifx) is an effective therapy for refractory luminal and fistulizing crohn's disease (cd). predictors of response could improve selection of patients with a higher probability of favorable outcomes and could improve the safety profile. we aimed to develop a predictive mode